Titlebook: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy; Vassil St.Georgiev,Gail Skowron (Chief),Joep M. A. Book 2006 Humana Press 2006 AIDS.

縮寫

書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy影響因子(影響力)




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy影響因子(影響力)學科排名




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy網絡公開度




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy網絡公開度學科排名




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy被引頻次




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy被引頻次學科排名




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy年度引用




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy年度引用學科排名




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy讀者反饋




書目名稱Reverse Transcriptase Inhibitors in HIV/AIDS Therapy讀者反饋學科排名

象形文字

長矛

Zidovudine, Lamivudine, and Abacavir,ot only because it was the first Food and Drug Administration (FDA)-approved agent for the treatment of HIV, but for the unprecedented speed with which this drug moved through the new-drug approval process (Table 1). In March 1987, ZDV was approved by the FDA for use in HIV-infected individuals with

radiograph

Stavudine, Didanosine, and Zalcitabine,nd in 1987, researchers logically turned to other nucleoside analogs in an attempt to expand the armamentarium against the disease. The next three compounds in this class to become commercially available were didanosine (as Videx?, Bristol Myers Squibb) in 1991, zalcitabine (as Hivid?, F. Hoffmann-L

Lament

Emtricitabine,ering only in having a fluoride at the 5-position of the cytosine ring. Emtricitabine is the (& minus) enantiomer, which is more active than the (+) enantiomer. Emtricitabine has a long plasma half-life (10 h), and even longer intracellular half-life of the active triphosphate (39 h), supporting onc

依法逮捕

left-ventricle

捐助

變色龍

happiness